Head-to-Head

Amneal Pharmaceuticals, Inc. Class A Common Stock vs. Johnson & Johnson

AMRX

Amneal Pharmaceuticals, Inc. Class A Common Stock

$17.01 +0.83%

VS JNJ

Johnson & Johnson

$271.63 +0.52%

Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 9 compared factors.

Size & Scale

AMRXJNJ
Market Cap $5.92 billion $651.20 billion
Revenue (TTM) $3.12 billion $97.93 billion
Net Income (TTM) $215.32 million $21.04 billion

JNJ leads on 3 of 3 size & scale factors.

Valuation

AMRXJNJ
P/E Ratio 34.71 31.51
Price / Book 179.40 7.66
Price / Sales 1.90 6.65

JNJ leads on 2 of 3 valuation factors.

Profitability

AMRXJNJ
Net Margin 6.91% 21.48%
Return on Equity 652.01% 24.76%

AMRX and JNJ split the profitability factors evenly.

Dividend

AMRXJNJ
Dividend Yield — 1.97%
Payout Ratio — 62.18

AMRX and JNJ split the dividend factors evenly.

Risk & Sentiment

AMRXJNJ
Short Interest 2.39% 0.67%

JNJ leads on 1 of 1 risk & sentiment factors.

Dig deeper: AMRX overview, AMRX financials, JNJ overview, JNJ financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.